Trials / Completed
CompletedNCT04472676
A Study of LY3473329 in Healthy Participants
A Safety, Tolerability, and Pharmacokinetic Study of Single-and Multiple-Ascending Doses of LY3473329 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3473329 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3473329 gets into the bloodstream and how long the body takes to eliminate it. This is a two-part study. Participants may only enroll in one part. For each participant: * Part A will last up to about 19 weeks and may include 9 visits. * Part B will last up to about 28 weeks and may include 11 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3473329 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2020-08-18
- Primary completion
- 2021-11-09
- Completion
- 2021-11-09
- First posted
- 2020-07-15
- Last updated
- 2021-12-14
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04472676. Inclusion in this directory is not an endorsement.